熱門資訊> 正文

Inhibrx Biosciences GAAP每股收益为-2.15美元

2026-05-15 04:46

Inhibrx Biosciences press release (INBX): Q1 GAAP EPS of -$2.15.
Cash and Cash Equivalents. As of March 31, 2026, the Company had cash and cash equivalents of $161.7 million, as compared to $124.2 million as of December 31, 2025. The Company's cash balance increased as a result of the receipt of gross proceeds of $75.0 million in March 2026 upon entering into the First Amendment to the Loan and Security Agreement (March 2026 Amendment) with Oxford Finance LLC (Oxford).

More on Inhibrx Biosciences

Inhibrx: Spinoff Rumors Send Shares Soaring - Stunning Bull Run Can Continue
Inhibrx Biosciences FY25 Review: Catalyst-Driven Hold Ahead Of Key 2026 Data
Inhibrx rises on upcoming interim mid-stage data for head and neck cancer asset
Inhibrx cancer drug reportedly drawing interest of Merck and rivals
Seeking Alpha’s Quant Rating on Inhibrx Biosciences

推薦文章

風險及免責提示：以上內容僅代表作者的個人立場和觀點，不代表華盛的任何立場，華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前，應結合自身情況，考慮投資產品的風險。必要時，請諮詢專業投資顧問的意見。華盛不提供任何投資建議，對此亦不做任何承諾和保證。